NTRK fusion-positive cancers and TRK inhibitor therapy

NTRK fusion-positive cancers and TRK inhibitor therapy<i>NTRK</i> fusion-positive cancers and TRK inhibitor therapy, Published online: 17 October 2018; doi:10.1038/s41571-018-0113-0TRK fusion proteins are pathognomonic is certain rare tumour types and present in a small subset of diverse cancer types, including some common cancers; TRK inhibitors have promising efficacy in the treatment of these cancers, in a histology-agnostic manner. In this Review, the biology of TRK signalling and TRK fusions, strategies to target these drivers, the unique safety profile of TRK inhibitors and mechanisms of and strategies to overcome acquired resistance to these agents are discussed.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research